Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

about

Rethinking End Points in Clinical Trials of Renoprotective Medication.

P2860

Q50035214-5366CD33-7053-42EB-8189-7F4B2F3A5178

P2860

Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

Item

http://www.wikidata.org/entity/Q47942386

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Is Chronic Dialysis the Right ...... e Renoprotective Drug Effects?

@en

Is Chronic Dialysis the Right ...... e Renoprotective Drug Effects?

@nl

type

Item

label

Is Chronic Dialysis the Right ...... e Renoprotective Drug Effects?

@en

Is Chronic Dialysis the Right ...... e Renoprotective Drug Effects?

@nl

prefLabel

Is Chronic Dialysis the Right ...... e Renoprotective Drug Effects?

@en

Is Chronic Dialysis the Right ...... e Renoprotective Drug Effects?

@nl

P1476

Is Chronic Dialysis the Right ...... e Renoprotective Drug Effects?

@en

P2093

Dick de Zeeuw

http://www.w3.org/2001/XMLSchema#string

Hiddo J L Heerspink

http://www.w3.org/2001/XMLSchema#string

Jamie P Dwyer

http://www.w3.org/2001/XMLSchema#string

P2860

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.

Factors influencing patient choice of dialysis versus conservative care to treat end-stage kidney disease.

Longitudinal progression trajectory of GFR among patients with CKD.

Factors influencing the decision to start renal replacement therapy: results of a survey among European nephrologists.

The GFR and GFR decline cannot be accurately estimated in type 2 diabetics.

Stewardship or clinical freedom? variations in dialysis decision making.

P304

1595-1600

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.09590916

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peter Mol

Misghina Weldegiorgis

P577

2017-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28923834

http://www.w3.org/2001/XMLSchema#string

P932

5628725

http://www.w3.org/2001/XMLSchema#string

Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

about

P2860

P2860

Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932